• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
RVA
Click for more information
0.00% 0.0¢

REVA MEDICAL, INC - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
RVA Change of Director's Interest Notice22/08/17
RVA Appendix 3B22/08/17
RVA Half Yearly Report and Accounts (Appendix 4D)PRICE SENSITIVE10/08/17
RVA Notice of Briefing Call07/08/17
RVA Boston Scientific Distribution Option LapsesPRICE SENSITIVE04/08/17
RVA Appendix 4C - quarterlyPRICE SENSITIVE31/07/17
RVA Initial Director's Interest Notice17/07/17
RVA Final Director's Interest Notice17/07/17
RVA Change of Director's Interest Notice17/07/17
RVA Change of Director's Interest Notice17/07/17
RVA Change of Director's Interest Notice17/07/17
RVA Change of Director's Interest Notice17/07/17
RVA Change of Director's Interest Notice17/07/17
RVA REVA Announces Organizational Changes14/07/17
RVA Appendix 3B12/07/17
RVA First Commercial CustomerPRICE SENSITIVE28/06/17
RVA Appendix 3B19/06/17
RVA Financing Completed -- Receipt of US$13.3 Million19/06/17
RVA Changes to Board of Directors09/06/17
RVA Initial Director's Interest Notice08/06/17
RVA Final Director's Interest Notice08/06/17
RVA Change of Director's Interest Notice08/06/17
RVA Change of Director's Interest Notice08/06/17
RVA Change of Director's Interest Notice08/06/17
RVA Change of Director's Interest Notice08/06/17
RVA Change of Director's Interest Notice08/06/17
RVA Change of Director's Interest Notice08/06/17
RVA Appendix 3B08/06/17
RVA AGM Results01/06/17
RVA AGM Presentation01/06/17
RVA Annual General Meeting Dial-In Details30/05/17
RVA REVA Symposium Showcases Clinical DataPRICE SENSITIVE18/05/17
RVA Final share buy-back notice - Appendix 3F18/05/17
RVA REVA Announces Positive 12-Month Clinical ResultsPRICE SENSITIVE17/05/17
RVA Proxy Statement for 2017 AGM16/05/17
RVA Quarterly Report on Form 10-QPRICE SENSITIVE10/05/17
RVA Issuance of Convertible Notes and Options05/05/17
RVA Amendment No. 1 to Form 10-K02/05/17
RVA Appendix 4C - quarterlyPRICE SENSITIVE28/04/17
RVA Notice of Briefing Call28/04/17
RVA Enrollment Initiated in Expanded FANTOM II TrialPRICE SENSITIVE26/04/17
RVA Prospectus for Offering of Convertible Notes and OptionsPRICE SENSITIVE24/04/17
RVA Convertible Note Financing ArrangedPRICE SENSITIVE24/04/17
RVA Announcement of buy-back - Appendix 3C24/04/17
RVA REVA to Present at EuroPCR 201712/04/17
RVA REVA Receives CE Mark for FantomPRICE SENSITIVE04/04/17
RVA Appendix 4G30/03/17
RVA Appendix 3B27/03/17
RVA FANTOM II Trial to be Expanded to More Complex CasesPRICE SENSITIVE24/03/17
RVA Appendix 4C - quarterly (revised)17/03/17
RVA Notice of Briefing Call09/03/17
RVA Form S-8 Filed with SEC01/03/17
RVA Preliminary Final Report and Annual Report on Form 10-KPRICE SENSITIVE28/02/17
RVA Change in substantial holding20/02/17
RVA Appendix 4C - quarterlyPRICE SENSITIVE31/01/17
RVA REVA to Present at J.P. Morgan Healthcare Conference10/01/17
RVA Appendix 3B28/12/16
RVA Appendix 3B29/11/16
RVA Quarterly Report on Form 10-Q10/11/16
RVA Amendment No. 1 to Form 10-QPRICE SENSITIVE09/11/16
RVA Notice of Briefing Call03/11/16
RVA Appendix 4C - quarterly-RVALL.PK PRICE SENSITIVE29/07/16
RVA Appendix 3B-RVALL.PK 27/07/16
RVA Change of Director's Interest Notice-RVALL.PK 27/07/16
RVA Change of Director's Interest Notice-RVALL.PK 27/07/16
RVA Change of Director's Interest Notice-RVALL.PK 27/07/16
RVA Change of Director's Interest Notice-RVALL.PK 26/07/16
RVA Change of Director's Interest Notice-RVALL.PK 20/07/16
RVA Change of Director's Interest Notice-RVALL.PK 20/07/16
RVA Change of Director's Interest Notice-RVALL.PK 20/07/16
RVA Insiders Purchasing Remaining Shares & Clinical Update-RVALL.PK 08/07/16
RVA Change of Director's Interest Notice31/03/16
RVA Brian Dovey Elected Chairman30/03/16
RVA Results of Special Meeting23/03/16
RVA Details for Special Meeting of Stockholders16/03/16
RVA Annual Report on Form 10-K11/03/16
RVA Form S-8 Filed with SEC11/03/16
RVA S&P DJ Indices Announces March Quarterly Review11/03/16
RVA Proxy Statement for Special Meeting of Stockholders09/03/16
RVA Notice of Briefing Call08/03/16
RVA Preliminary Final ReportPRICE SENSITIVE26/02/16
RVA FANTOM II Target Patient Enrollment AchievedPRICE SENSITIVE24/02/16
RVA Appendix 3B22/02/16
RVA Notice of Change of Substantial Holders16/02/16
RVA Becoming a substantial holder16/02/16
RVA Appendix 3B16/02/16
RVA Clinical Progress & Anticipated $11.4 Million Cash ReceiptPRICE SENSITIVE11/02/16
RVA Appendix 4C - quarterlyPRICE SENSITIVE29/01/16
RVA Richard Kimes Hired as SVP of Operations20/01/16
RVA Presentation at J.P. Morgan Healthcare Conference15/01/16
RVA REVA to Present at J.P. Morgan Healthcare Conference08/01/16
RVA Appendix 3B17/12/15
RVA Notice of Change of Substantial Holders23/11/15
RVA Quarterly Report on Form 10-QPRICE SENSITIVE10/11/15
RVA Notice of Briefing Call06/11/15
RVA Appendix 4C - quarterlyPRICE SENSITIVE30/10/15
RVA Presentation of Initial Fantom Results at TCT16/10/15
RVA Fantom Presentation at Next-Generation Session15/10/15
RVA Becoming a substantial holder06/10/15
RVA Appendix 3B06/10/15
RVA Change of Director's Interest Notice
22/08/17
RVA Appendix 3B
22/08/17
RVA Half Yearly Report and Accounts (Appendix 4D)
10/08/17PRICE SENSITIVE
RVA Notice of Briefing Call
07/08/17
RVA Boston Scientific Distribution Option Lapses
04/08/17PRICE SENSITIVE
RVA Appendix 4C - quarterly
31/07/17PRICE SENSITIVE
RVA Initial Director's Interest Notice
17/07/17
RVA Final Director's Interest Notice
17/07/17
RVA Change of Director's Interest Notice
17/07/17
RVA Change of Director's Interest Notice
17/07/17
RVA Change of Director's Interest Notice
17/07/17
RVA Change of Director's Interest Notice
17/07/17
RVA Change of Director's Interest Notice
17/07/17
RVA REVA Announces Organizational Changes
14/07/17
RVA Appendix 3B
12/07/17
RVA First Commercial Customer
28/06/17PRICE SENSITIVE
RVA Appendix 3B
19/06/17
RVA Financing Completed -- Receipt of US$13.3 Million
19/06/17
RVA Changes to Board of Directors
09/06/17
RVA Initial Director's Interest Notice
08/06/17
RVA Final Director's Interest Notice
08/06/17
RVA Change of Director's Interest Notice
08/06/17
RVA Change of Director's Interest Notice
08/06/17
RVA Change of Director's Interest Notice
08/06/17
RVA Change of Director's Interest Notice
08/06/17
RVA Change of Director's Interest Notice
08/06/17
RVA Change of Director's Interest Notice
08/06/17
RVA Appendix 3B
08/06/17
RVA AGM Results
01/06/17
RVA AGM Presentation
01/06/17
RVA Annual General Meeting Dial-In Details
30/05/17
RVA REVA Symposium Showcases Clinical Data
18/05/17PRICE SENSITIVE
RVA Final share buy-back notice - Appendix 3F
18/05/17
RVA REVA Announces Positive 12-Month Clinical Results
17/05/17PRICE SENSITIVE
RVA Proxy Statement for 2017 AGM
16/05/17
RVA Quarterly Report on Form 10-Q
10/05/17PRICE SENSITIVE
RVA Issuance of Convertible Notes and Options
05/05/17
RVA Amendment No. 1 to Form 10-K
02/05/17
RVA Appendix 4C - quarterly
28/04/17PRICE SENSITIVE
RVA Notice of Briefing Call
28/04/17
RVA Enrollment Initiated in Expanded FANTOM II Trial
26/04/17PRICE SENSITIVE
RVA Prospectus for Offering of Convertible Notes and Options
24/04/17PRICE SENSITIVE
RVA Convertible Note Financing Arranged
24/04/17PRICE SENSITIVE
RVA Announcement of buy-back - Appendix 3C
24/04/17
RVA REVA to Present at EuroPCR 2017
12/04/17
RVA REVA Receives CE Mark for Fantom
04/04/17PRICE SENSITIVE
RVA Appendix 4G
30/03/17
RVA Appendix 3B
27/03/17
RVA FANTOM II Trial to be Expanded to More Complex Cases
24/03/17PRICE SENSITIVE
RVA Appendix 4C - quarterly (revised)
17/03/17
RVA Notice of Briefing Call
09/03/17
RVA Form S-8 Filed with SEC
01/03/17
RVA Preliminary Final Report and Annual Report on Form 10-K
28/02/17PRICE SENSITIVE
RVA Change in substantial holding
20/02/17
RVA Appendix 4C - quarterly
31/01/17PRICE SENSITIVE
RVA REVA to Present at J.P. Morgan Healthcare Conference
10/01/17
RVA Appendix 3B
28/12/16
RVA Appendix 3B
29/11/16
RVA Quarterly Report on Form 10-Q
10/11/16
RVA Amendment No. 1 to Form 10-Q
09/11/16PRICE SENSITIVE
RVA Notice of Briefing Call
03/11/16
RVA Appendix 4C - quarterly-RVALL.PK
29/07/16PRICE SENSITIVE
RVA Appendix 3B-RVALL.PK
27/07/16
RVA Change of Director's Interest Notice-RVALL.PK
27/07/16
RVA Change of Director's Interest Notice-RVALL.PK
27/07/16
RVA Change of Director's Interest Notice-RVALL.PK
27/07/16
RVA Change of Director's Interest Notice-RVALL.PK
26/07/16
RVA Change of Director's Interest Notice-RVALL.PK
20/07/16
RVA Change of Director's Interest Notice-RVALL.PK
20/07/16
RVA Change of Director's Interest Notice-RVALL.PK
20/07/16
RVA Insiders Purchasing Remaining Shares & Clinical Update-RVALL.PK
08/07/16
RVA Change of Director's Interest Notice
31/03/16
RVA Brian Dovey Elected Chairman
30/03/16
RVA Results of Special Meeting
23/03/16
RVA Details for Special Meeting of Stockholders
16/03/16
RVA Annual Report on Form 10-K
11/03/16
RVA Form S-8 Filed with SEC
11/03/16
RVA S&P DJ Indices Announces March Quarterly Review
11/03/16
RVA Proxy Statement for Special Meeting of Stockholders
09/03/16
RVA Notice of Briefing Call
08/03/16
RVA Preliminary Final Report
26/02/16PRICE SENSITIVE
RVA FANTOM II Target Patient Enrollment Achieved
24/02/16PRICE SENSITIVE
RVA Appendix 3B
22/02/16
RVA Notice of Change of Substantial Holders
16/02/16
RVA Becoming a substantial holder
16/02/16
RVA Appendix 3B
16/02/16
RVA Clinical Progress & Anticipated $11.4 Million Cash Receipt
11/02/16PRICE SENSITIVE
RVA Appendix 4C - quarterly
29/01/16PRICE SENSITIVE
RVA Richard Kimes Hired as SVP of Operations
20/01/16
RVA Presentation at J.P. Morgan Healthcare Conference
15/01/16
RVA REVA to Present at J.P. Morgan Healthcare Conference
08/01/16
RVA Appendix 3B
17/12/15
RVA Notice of Change of Substantial Holders
23/11/15
RVA Quarterly Report on Form 10-Q
10/11/15PRICE SENSITIVE
RVA Notice of Briefing Call
06/11/15
RVA Appendix 4C - quarterly
30/10/15PRICE SENSITIVE
RVA Presentation of Initial Fantom Results at TCT
16/10/15
RVA Fantom Presentation at Next-Generation Session
15/10/15
RVA Becoming a substantial holder
06/10/15
RVA Appendix 3B
06/10/15
refresh Created with Sketch. REFRESH
 

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
Anteris Tech eyes US market liquidity with early-stage NASDAQ IPO paperwork Anteris Technologies (ASX:AVR) revealed on Monday it's sent off early-stage paperwork to the US regulator for a proposed NASDAQ IPO.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.